KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Payables (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Payables for 8 consecutive years, with $65.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 38.75% year-over-year to $65.1 million, compared with a TTM value of $65.1 million through Dec 2025, down 38.75%, and an annual FY2025 reading of $65.1 million, down 38.75% over the prior year.
  • Payables was $65.1 million for Q4 2025 at Esperion Therapeutics, down from $132.4 million in the prior quarter.
  • Across five years, Payables topped out at $132.4 million in Q3 2025 and bottomed at $12.8 million in Q2 2022.
  • Average Payables over 5 years is $47.5 million, with a median of $28.9 million recorded in 2021.
  • The sharpest move saw Payables plummeted 66.22% in 2021, then soared 345.48% in 2025.
  • Year by year, Payables stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then surged by 37.66% to $31.7 million in 2023, then surged by 234.9% to $106.2 million in 2024, then crashed by 38.75% to $65.1 million in 2025.
  • Business Quant data shows Payables for ESPR at $65.1 million in Q4 2025, $132.4 million in Q3 2025, and $129.5 million in Q2 2025.